Q1 EPS Forecast for Amicus Therapeutics Increased by Analyst

Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Investment analysts at Zacks Research lifted their Q1 2026 EPS estimates for shares of Amicus Therapeutics in a report issued on Tuesday, April 1st. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings of $0.06 per share for the quarter, up from their previous estimate of $0.04. The consensus estimate for Amicus Therapeutics’ current full-year earnings is $0.15 per share. Zacks Research also issued estimates for Amicus Therapeutics’ Q2 2026 earnings at $0.07 EPS, Q4 2026 earnings at $0.13 EPS, FY2026 earnings at $0.36 EPS, Q1 2027 earnings at $0.10 EPS and FY2027 earnings at $0.56 EPS.

Other research analysts also recently issued reports about the company. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 price target on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Morgan Stanley reiterated an “equal weight” rating and issued a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. StockNews.com cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 20th. Finally, Wells Fargo & Company lowered their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, February 20th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.75.

Amicus Therapeutics Stock Performance

FOLD opened at $7.95 on Wednesday. The company has a market capitalization of $2.44 billion, a price-to-earnings ratio of -44.17, a P/E/G ratio of 1.51 and a beta of 0.69. The business’s 50-day moving average price is $9.22 and its two-hundred day moving average price is $9.91. Amicus Therapeutics has a 1 year low of $7.76 and a 1 year high of $12.65. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Virtus Fund Advisers LLC acquired a new stake in Amicus Therapeutics in the 4th quarter valued at about $29,000. Covestor Ltd raised its stake in Amicus Therapeutics by 114.9% in the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 2,312 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Amicus Therapeutics in the third quarter valued at approximately $55,000. GF Fund Management CO. LTD. bought a new position in shares of Amicus Therapeutics during the 4th quarter worth approximately $59,000. Finally, R Squared Ltd acquired a new position in shares of Amicus Therapeutics during the 4th quarter worth approximately $79,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.